Document Detail

Nanomedicine in chemoradiation.
MedLine Citation:
PMID:  23343162     Owner:  NLM     Status:  MEDLINE    
Chemoradiotherapy, the concurrent administration of chemotherapy and radiotherapy, is a treatment paradigm in oncology. It is part of the standard of care and curative treatment of many cancers. Given its importance, one of the primary goals of cancer research has been to identify agents and/or strategies that can improve the therapeutic index of chemoradiation. Recent advances in nanomedicine have provided a unique and unprecedented opportunity for improving chemoradiotherapy. Nanoparticles possess properties that are ideally suited for delivering chemotherapy in the chemoradiation setting. The goal of this review is to examine the role of incorporating nanomedicine into chemoradiation and the potential impact of nanomedicine to chemoradiotherapy.
Seth M Miller; Andrew Z Wang
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Therapeutic delivery     Volume:  4     ISSN:  2041-5990     ISO Abbreviation:  Ther Deliv     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-24     Completed Date:  2013-03-07     Revised Date:  2013-12-04    
Medline Journal Info:
Nlm Unique ID:  101538870     Medline TA:  Ther Deliv     Country:  England    
Other Details:
Languages:  eng     Pagination:  239-50     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / administration & dosage,  therapeutic use
Chemoradiotherapy / methods*
Nanomedicine / methods*
Neoplasms / therapy*
Grant Support
1-U54-CA151652-01/CA/NCI NIH HHS; 5-K12-CA120780-01-05/CA/NCI NIH HHS; K12 CA120780/CA/NCI NIH HHS; U54 CA151652/CA/NCI NIH HHS
Reg. No./Substance:
0/Antineoplastic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Physicochemical property trends of marketed prodrugs.
Next Document:  Drug carriers for oral delivery of peptides and proteins: accomplishments and future perspectives.